title: Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children.
abstract: BACKGROUND
  A prospective nationwide screening study initiated more than 20 years ago in Sweden has shown that clinically significant liver disease develops in only 10% to 15% of alpha1-antitrypsin (AT)-deficient children. This study provides information about 85% to 90% of those children, many of whom had elevated serum transaminases in infancy but have no evidence of liver injury by age 18 years. However, there is relatively limited information about the course of alpha1-AT-deficient children who have cirrhosis or portal hypertension. Based on several anecdotal experiences, we have been impressed by the relatively slow progression and stable course of the liver disease in some of these children.
  
  
  METHODS
  We reviewed the course of patients with homozygous PIZZ alpha1-antitrypsin deficiency seen at this institution since establishing a patient database 16 years ago.
  
  
  RESULTS
  Of 44 patients with alpha1-AT deficiency, 17 had cirrhosis, portal hypertension, or both. Nine of the 17 patients with cirrhosis or portal hypertension had a prolonged, relatively uneventful course for at least 4 years after the diagnosis of cirrhosis or portal hypertension. Two of these patients eventually underwent liver transplantation, but seven are leading relatively healthy lives for up to 23 years while carrying a diagnosis of severe alpha1-AT deficiency-associated liver disease. Patients with the prolonged stable course could be distinguished from those with a rapidly progressive course on the basis of overall life functioning but not on the basis of any other more conventional clinical or biochemical criteria.
  
  
  CONCLUSIONS
  These data provide further evidence for the variable severity of liver disease associated with alpha1-AT deficiency and indicate that some patients have chronic, slowly progressing or nonprogressing cirrhosis.
authors.affiliation: Department of Pediatrics, Washington University School of Medicine and St. Louis Children's Hospital, Missouri 63110, USA.
authors.forename: D
authors.initials: D
authors.lastname: Volpert
authors.forename: J P
authors.initials: JP
authors.lastname: Molleston
authors.forename: D H
authors.initials: DH
authors.lastname: Perlmutter
mesh_terms: D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006975:Hypertension, Portal / Q000201:enzymology / Q000209:etiology* / Q000628:therapy; D007223:Infant; D007231:Infant, Newborn; D008103:Liver Cirrhosis / Q000201:enzymology / Q000209:etiology* / Q000628:therapy; D016031:Liver Transplantation; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications*; D010641:Phenotype; D011379:Prognosis; D011788:Quality of Life; D012189:Retrospective Studies; D019896:alpha 1-Antitrypsin Deficiency / Q000150:complications*